Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
Zelira Therapeutics accelerates towards commercialisation in 2020
Kazia Therapeutics to share pipeline results with market and clinicians
Only registered members can use this feature.
Copyright © Proactive Investors 2019.
All Rights Reserved - Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.